IPP Bureau
U.S. FDA advisory committee recommends J&J booster dose
By IPP Bureau - October 18, 2021
U.S. FDA to decide whether to authorize a booster dose in the coming days
Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
By IPP Bureau - October 18, 2021
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Resilience and Harvard announce five-year R&D alliance
By IPP Bureau - October 18, 2021
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
GPT Healthcare to go public to fund expansion
By IPP Bureau - October 18, 2021
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
Granules gets ANDA approval for Dofetilide capsules
By IPP Bureau - October 18, 2021
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Govt. removes export curbs on Covid-19 kits
By IPP Bureau - October 16, 2021
The export policy of all diagnostic kits and reagents (including instruments /apparatus) ... is being made free with immediate effect," the directorate general of foreign trade (DGFT) said in a notification
Metropolis Healthcare board approves acquisition of Hitech for Rs 636 crore
By IPP Bureau - October 16, 2021
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
Dr Reddy’s Lab launches carmustine in the US market
By IPP Bureau - October 16, 2021
The BiCNU brand and generic market had U.S. sales of approximately US $ 19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health
Lancet Respiratory Medicine publishes Phase 2 data of Medigen Covid-19 vaccine
By IPP Bureau - October 16, 2021
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
Exelixis in-licenses second anti-cancer compound from Aurigene
By IPP Bureau - October 15, 2021
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
AUM Biosciences closes US $ 27 million `Series A’ funding round
By IPP Bureau - October 15, 2021
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Expect normal quarter in Q2FY22: Emkay
By IPP Bureau - October 15, 2021
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
.jpg "Smith’s Detection confirms BioFlash detects airborne Covid-19")
Smith’s Detection confirms BioFlash detects airborne Covid-19
By IPP Bureau - October 14, 2021
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
Hospitals to accelerate digital investments: Frost & Sullivan
By IPP Bureau - October 14, 2021
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis
By IPP Bureau - October 14, 2021
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
